

Open Peer Review on Qeios

FGFR4 Inhibitor ICP-105

National Cancer Institute

Source

National Cancer Institute. FGFR4 Inhibitor ICP-105. NCI Thesaurus. Code C162852.

An orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon oral administration, ICP-105 specifically targets, binds to and blocks the binding of the ligand FGF19 to FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell proliferation in FGFR4-overexpressing cells. FGFR4, a receptor tyrosine kinase overexpressed on a variety of cancer cell types, is involved in tumor cell proliferation, differentiation, angiogenesis, and survival. FGF19 is overexpressed by certain tumor cell types.

Qeios ID: 736A1Z · https://doi.org/10.32388/736A1Z